Gates Foundation Offers USD$100K Grants for Innovative Global Health and Development Projects

The Bill & Melinda Gates Foundation announced today that it is accepting applications for Round 10 of its Grand Challenges Explorations initiative, a USD$100 million grant initiative encouraging innovation in global health and development research.  Anyone with a transformative idea is invited to submit an easy, online, two page application.

Grand Challenges Explorations is pleased to have the opportunity to again partner with Cannes Lions on a topic that will identify new ways to communicate the impact of investments that support global development. It includes four specific submission categories for grant seekers. We hope these will solicit unique proposals from innovators around the world that the foundation can support as part of its overall mission to alleviate global poverty.

Topics for Grand Challenges Explorations Round 10:

  • Aid is Working, Tell the World (Part 2)  (in partnership with Cannes Lions )
  • Labor Saving Innovations for Women Smallholder Farmers (new!)
  • New Approaches in Model Systems, Diagnostics, and Drugs for Specific Neglected Tropical Diseases (new!)
  • New Approaches for the Interrogation of Anti-Malarial Compounds

“Bold thinking from the world’s innovators can address health and development challenges and make a big difference in the lives of those most in need,” said Chris Wilson, Director of Global Health Discovery & Translational Sciences at the Bill & Melinda Gates Foundation.  “We seek pioneering proposals that have the potential to improve the lives of millions.”

The Gates Foundation and an independent group of reviewers will select the most innovative proposals, and grants will be awarded within approximately five months from the proposal submission deadline. Initial grants will be USD$100,000 each. Projects demonstrating potential will have the opportunity to receive additional funding up to USD$1 million.

Proposals are being accepted at the Grand Challenges website through November 7, 2012. Applicants from Africa, Asia, and the developing world are encouraged to apply.

Source: Bill & Melinda Gates Foundation

Genetically Engineered Bacteria Prevent Mosquitoes From Transmitting Malaria

Researchers at the Johns Hopkins Malaria Research Institute have genetically modified a bacterium commonly found in the mosquito’s midgut and found that the parasite that causes malaria in people does not survive in mosquitoes carrying the modified bacterium. The bacterium, Pantoea agglomerans, was modified to secrete proteins toxic to the malaria parasite, but the toxins do not harm the mosquito or humans. According to a study published by PNAS, the modified bacteria were 98 percent effective in reducing the malaria parasite burden in mosquitoes.

“In the past, we worked to genetically modify the mosquito to resist malaria, but genetic modification of bacteria is a simpler approach,” said Marcelo Jacobs-Lorena, PhD, senior author of the study and a professor with Johns Hopkins Bloomberg School of Public Health. “The ultimate goal is to completely prevent the mosquito from spreading the malaria parasite to people.”

With the study, Jacobs-Lorena and his colleagues found that the engineered P. agglomerans strains inhibited development of the deadliest human malaria parasite Plasmodium falciparum and rodent malaria parasite Plasmodium berghei by up to 98 percent within the mosquito. The proportion of mosquitoes carrying parasites (prevalence) decreased by up to 84 percent.

“We demonstrate the use of an engineered symbiotic bacterium to interfere with the development of P. falciparum in the mosquito. These findings provide the foundation for the use of genetically modified symbiotic bacteria as a powerful tool to combat malaria,” said Jacobs-Lorena.

Malaria kills more than 800,000 people worldwide each year. Many are children.

The authors of “Fighting malaria with engineered symbiotic bacteria from vector mosquitoes” are Sibao Wang, Anil K. Ghosh, Nicholas Bongio, Kevin A. Stebbings, David J. Lampe and Marcelo Jacobs-Lorena.

The research was supported by National Institute of Allergy and Infectious Diseases, the Bill & Melinda Gates Foundation, the Johns Hopkins Malaria Research Institute and the Bloomberg Family Foundation.

Source: Johns Hopkins Bloomberg School of Public Health

Glaxo’s RTS,S Malaria Vaccine Shows Promise

Preliminary results from the trial of a malaria vaccine show that it protected nearly half of the children who received it from bouts of serious malaria, scientists said Tuesday. The vaccine, known as RTS,S and made by GlaxoSmithKline, has been in development for more than 25 years, initially for the American military and now with most of its support from the Bill and Melinda Gates Foundation. [Read more…]

RTS,S Malaria Vaccine

QUESTION:

What information can you provide on this vaccine candidate?

ANSWER:

RTS,S is a vaccine candidate against Plasmodium falciparum malaria which works by encouraging the host’s body to produce antibodies and T cells which diminish the malaria parasite’s ability to survive and reproduce in the liver.

Produced by GlaxoSmithKline, RTS,S is the first vaccine candidate against Plasmodium falciparum that has reached advanced (Phase III) clinical field trials on a large scale. It was developed way back in 1987, and had successive trials in the United States in 1992 and then in Africa in 1998. In 2001, GSK and the Malaria Vaccine Initiative at PATH went into a public-private partnership, with grant money from the Bill and Melinda Gates Foundation, to develop the vaccine for use in children and infants in sub-Saharan Africa.

The Phase III trials are currently underway in a number of African countries; if all goes to plan, the vaccine will be submitted for regulation by drug authorities as early as 2012. This information, and more, can be found courtesy of the Malaria Vaccine Initiative website: http://www.malariavaccine.org/index.php.

Researchers to Develop Mobile Phone Based Malaria Detector

The University of Glasgow has received a grant from the Bill & Melinda Gates Foundation to further help in the diagnosis of malaria. The $100,000 award will go towards developing a device which uses mobile-phone derived technology that can detect and separate red blood cells infected with malaria parasites.

It is hoped that if successful, devices based on the technology could be mass produced for rapid and accurate malaria diagnosis. [Read more…]

Researchers Discover Insect Repellent Thousands of Times More Effective than DEET

Imagine an insect repellent that not only is thousands of times more effective than DEET – the active ingredient in most commercial mosquito repellents – but also works against all types of insects, including flies, moths and ants.

That possibility has been created by the discovery of a new class of insect repellent made in the laboratory of Vanderbilt Professor of Biological Sciences and Pharmacology Laurence Zwiebel and reported this week in the online Early Edition of the Proceedings of the National Academy of Sciences.

“It wasn’t something we set out to find,” said David Rinker, a graduate student who performed the study in collaboration with graduate student Gregory Pask and post-doctoral fellow Patrick Jones. “It was an anomaly that we noticed in our tests.”

The tests were conducted as part of a major interdisciplinary research project to develop new ways to control the spread of malaria by disrupting a mosquito’s sense of smell supported by the Grand Challenges in Global Health Initiative funded by the Foundation for the NIH through a grant from the Bill & Melinda Gates Foundation.

“It’s too soon to determine whether this specific compound can act as the basis of a commercial product,” Zwiebel cautioned. “But it is the first of its kind and, as such, can be used to develop other similar compounds that have characteristics appropriate for commercialization.”

The discovery of this new class of repellent is based on insights that scientists have gained about the basic nature of the insect’s sense of smell in the last few years. Although the mosquito’s olfactory system is housed in its antennae, 10 years ago biologists thought that it worked in the same way at the molecular level as it does in mammals. A family of special proteins called odorant receptors, or ORs, sits on the surface of nerve cells in the nose of mammals and in the antennae of mosquitoes. When these receptors come into contact with smelly molecules, they trigger the nerves signaling the detection of specific odors.

In the last few years, however, scientists have been surprised to learn that the olfactory system of mosquitoes and other insects is fundamentally different. In the insect system, conventional ORs do not act autonomously. Instead, they form a complex with a unique co-receptor (called Orco) that is also required to detect odorant molecules. ORs are spread all over the antennae and each responds to a different odor. To function, however, each OR must be connected to an Orco.

“Think of an OR as a microphone that can detect a single frequency,” Zwiebel said. “On her antenna the mosquito has dozens of types of these microphones, each tuned to a specific frequency. Orco acts as the switch in each microphone that tells the brain when there is a signal. When a mosquito smells an odor, the microphone tuned to that smell will turn “on” its Orco switch. The other microphones remain off. However, by stimulating Orco directly we can turn them all on at once. This would effectively overload the mosquito’s sense of smell and shut down her ability to find blood.”

Because the researchers couldn’t predict what chemicals might modulate OR-Orco complexes, they decided to “throw the kitchen sink” at the problem. Through their affiliation with Vanderbilt’s Institute of Chemical Biology, they gained access to Vanderbilt’s high throughput screening facility, a technology intended for the drug discovery process, not for the screening of insect ORs.

Jones used genetic engineering techniques to insert mosquito odorant receptors into the human embryonic kidney cells used in the screening process. Rinker tested these cells against a commercial library of 118,000 small molecules normally used in drug development. They expected to find, and did find, a number of compounds that triggered a response in the conventional mosquito ORs they were screening, but they were surprised to find one compound that consistently triggered OR-Orco complexes, leading them to conclude that they had discovered the first molecule that directly stimulates the Orco co-receptor. They have named the compound VUAA1.

Although it is not an odorant molecule, the researchers determined that VUAA1 activates insect OR-Orco complexes in a manner similar to a typical odorant molecule. Jones also verified that mosquitoes respond to exposure to VUAA1, a crucial step in demonstrating that VUAA1 can affect a mosquito’s behavior.

“If a compound like VUAA1 can activate every mosquito OR at once, then it could overwhelm the insect’s sense of smell, creating a repellent effect akin to stepping onto an elevator with someone wearing too much perfume, except this would be far worse for the mosquito,” Jones said.

The researchers have just begun behavioral studies with the compound. In preliminary tests with mosquitoes, they have found that VUAA1 is thousands of times more effective than DEET.

They have also established that the compound stimulates the OR-Orco complexes of flies, moths and ants. As a result, “VUAA1 opens the door for the development of an entirely new class of agents, which could be used not only to disrupt disease vectors, but also the nuisance insects in your backyard or the agricultural pests in your crops,” Jones said.

Many questions must be answered before VUAA1 can be considered for commercial applications. Zwiebel’s team is currently working with researchers in Vanderbilt’s Drug Discovery Program to pare away the parts of VUAA1 that don’t contribute to its activity. Once that is done, they will begin testing its toxicity.

Vanderbilt University has filed for a patent on this class of compounds and is talking with potential corporate licensees interested in incorporating them into commercial products, with special focus on development of products to reduce the spread of malaria in the developing world.

Source: Proceedings of the National Academy of Sciences, Vanderbilt University

 

Principles of Magnetic Levitation and Cell Phone Technology to Be Studied for Malaria Diagnosis Tools

The Gates Foundation has funded a project at Beth Israel Deaconess Medical Center (BIDMC) that uses the principles of magnetic levitation and cell phone technology to create an inexpensive, portable device to quickly and accurately diagnose malaria outside of the laboratory setting. The GCE received more than 2,500 grant submissions from 100 countries, and selected 88 projects, including that of Ionita Ghiran, MD, an investigator in the Division of Allergy and Inflammation at BIDMC, and Assistant Professor of Medicine at Harvard Medical School. Ghiran has been awarded a $100,000 Grand Challenges Exploration Grant from the Bill & Melinda Gates Foundation. The Grand Challenges Exploration (GCE) program funds scientists and researchers worldwide in the pursuit of novel ideas that can break the mold in solving persistent global health challenges.

“GCE winners are expanding the pipeline of ideas for serious global health and development challenges where creative thinking is most urgently needed,” said Chris Wilson, director of Global Health Discovery at the Bill & Melinda Gates Foundation. “These grants are meant to spur on new discoveries that could ultimately help save millions of lives.”

Malaria causes nearly 1 million deaths per year throughout developing countries (85 percent of which are children under the age of 5) and parasites are becoming increasingly resistant to anti-malarial drugs, in part due to overdiagnosis.

“The lack of suitable methods of malaria diagnosis makes presumptive treatment often the only available option for local health service providers,” notes Ghiran. To address this challenge, Ghiran, in collaboration with Pierre Striehl, PhD, from the Harvard School of Dental Medicine, developed an antibody-free diagnostic screening device which separates malaria-infected red blood cells from uninfected red blood cells by way of magnetic levitation.

“Our screening device is light-weight, disposable and inexpensive to manufacture,” he notes. The prototype system requires less than a drop of finger-prick blood and a small volume of red-blood-cell friendly buffer containing paramagnetic ions. Diagnostic results can be obtained within a few minutes solely by using a set of permanent magnets immobilized in a plastic structure surrounding a glass or plastic capillary containing the blood. Results are visualized, recorded and stored using a standard camera phone. No additional imaging equipment, or staining reagents are required.

“This method helps fill the need for malarial diagnostic technologies capable of promptly and reliably ascertaining true malarial infections in the field,” says Ghiran. “We hope that this will help prevent the overdiagnosis of malaria and subsequent drug resistance.”

Grand Challenges Explorations is a $100 million initiative funded by the Bill & Melinda Gates Foundation. Launched in 2008, Grand Challenge Explorations grants have already been awarded to nearly 500 researchers from over 40 countries. The grant program is open to anyone from any discipline and from any organization. The initiative uses an agile, accelerated grant-making process with short two-page online applications and no preliminary data required. Initial grants of $100,000 are awarded two times a year. Successful projects have the opportunity to receive a follow-up grant of up to $1 million.

Source: Beth Israel Deaconess Medical Center

New Biomarkers Study Could Lead to Improved Malaria Vaccines

In the first study of its type in the malaria field, Seattle BioMed has been awarded an $8.9 million grant from the Bill & Melinda Gates Foundation to identify biomarkers that will allow malaria vaccine design based on robust predictors of protective immunity.

According to Ruobing Wang, M.D., Ph.D., the goal of the study is to identify and validate biomarkers that correlate with vaccine-induced protective immunity against malaria infection.

“In order to bring the burden of malaria under control – with the ultimate goal of eradicating the pathogens that cause disease – we know we need a highly efficacious anti-infection vaccine,” she explained. “But, without reliable biomarkers of anti-infection immunity, the development and testing of malaria vaccines is a slow and expensive process.” Biomarkers will be used for prediction and monitoring the vaccine efficacy in clinical trials and to select optimal vaccine candidates for development.

To conduct this research, the company will call upon its areas of expertise and knowledge – vaccine and immunology studies in animal models of malaria, the ability to grow human malaria parasites in mosquitoes for research and clinical studies, and its ability to develop genetically attenuated parasite strains for human trials. It will also begin full-scale trials in its Malaria Clinical Trials Center, and employ its newfound expertise in the area of systems biology.

Seattle BioMed scientists have developed genetically attenuated whole parasite vaccine strains that have proven successful in rodent malaria models and have moved into human studies. “In this new study, we will use genetically attenuated parasite strains as probes to determine whether host correlates of immunity can be identified during vaccination in mice,” explained Seattle BioMed’s Stefan Kappe, Ph.D. “These model vaccines provide an opportunity to discriminate biomarkers associated with complete, long-lasting protection from those associated with partial, short-lived or lack of protection.”

Researchers at Seattle BioMed will then apply the knowledge gained in mouse models to human studies. “Through studies conducted at Seattle BioMed’s Malaria Clinical Trials Center, we’ll evaluate whether biomarkers of protection identified in the rodent models will predict protective immunity in humans,” explained Wang.

Seattle BioMed researchers will employ network analysis of transcriptional responses to predict protection in both mice and humans to determine if they can find universal markers that will allow them to optimize vaccine candidates. According to Alan Aderem, Ph.D., the power of systems biology lies in its capacity to predict the behavior of a biological system.  “If we have the ability to predict whether a vaccine candidate for malaria will work before it goes into large scale clinical trials, we could move away from today’s typical ‘trial and error’ method toward a more powerful predictive approach to vaccine discovery and development,” he said.

Through these integrated studies, Seattle BioMed researchers will deliver a set of candidate immune biomarkers associated with protection against malaria infection that can be used for monitoring vaccine efficacy. “This will facilitate future malaria vaccine trials with the ultimate goal of accelerating the development of a highly effective malaria vaccine that has the potential to save millions of lives,” said Wang.

Wang is leading the study – Seattle BioMed’s first to include the integration of its recently announced systems biology approach to infectious disease research – with a team that includes Seattle BioMed’s Stefan Kappe, Ph.D., and Alan Aderem, Ph.D., along with Patrick Duffy, M.D., of the National Institutes of Health, Jonathan Derry, Ph.D., of Sage Bionetworks, and Xiaowu Liang, Ph.D., of Antigen Discovery Inc. (ADi).

Source: PR Newswire

The Institute for OneWorld Health Announces Development of Alternative Source of Artemisinin

The Institute for OneWorld Health (iOWH), a non-profit drug development organization, announced today that its development of an alternative source of artemisinin using pioneering synthetic biology technology (semisynthetic artemisinin (ART) project) has successfully entered the production and distribution phase.

The semisynthetic version of artemisinin is targeted to be an affordable, non-seasonal and complementary source of ART and will stabilize price volatility and alleviate shortages – key factors in meeting future demand in developing nations and around the globe.

iOWH, in collaboration with its strategic partners, successfully completed the scientific work necessary to enter the production and distribution phase of the project. Through a unique public-private partnership with sanofi-aventis, a leading global pharmaceutical company, this phase will enable production of semisynthetic ART. Sanofi has made essential contributions during the project’s development and industrialization phase, and is going to manufacture and distribute the semi synthetic artemisinin version to any qualified buyer. The substantial investment sanofi-aventis is making in this project will make it possible to facilitate integration of semisynthetic ART into the ACTs and the global supply chain, with an estimated goal to begin distribution in 2012.

“When we started work on this project, nearly six years ago, we knew that this would be a major challenge from technical, scientific, and humanitarian standpoints. Here we are today; however, ready to begin the production and distribution phase in collaboration with sanofi, thanks to the hard work of our team, our collaborators, and our subgrantees, as well as generous support from our funders. Our goal is that one day; no child will die from malaria. Providing an alternative source of artemisinin is a breakthrough in the fight against malaria,” said Richard Chin, M.D., CEO of iOWH.

“Realizing this project brings us enormous satisfaction that only our profession, devoted to public health and patient care, can offer. Contributing to a project which saves lives and relieves suffering within the context of a fair trade economic model, combined with technological challenges and partnership, is a source of inspiration for all members of our team,” said Francis Carré, CEO of Sanofi Chimie.

iOWH has led this project, funded by the Bill & Melinda Gates Foundation, in collaboration with Amyris Inc. and sanofi-aventis. The synthetic biology technology is based on pioneering inventions licensed from the University of California at Berkeley and the University of Saskatchewan. Headquartered in South San Francisco, iOWH is a non-profit that discovers, develops and delivers safe, effective and affordable new medicines for vulnerable population with infectious diseases in the developing world, with emphasis on diseases that disproportionately affect children.

Source: Business Wire

Pharma Service Company Quintiles Selected for Gates Foundation Consortium Clinical Trials Work

Quintiles,an integrated biopharmaceutical company, has been named a preferred provider to a consortium of 14 global health Product Development Partnerships (PDPs), funded in part by the Bill and Melina Gates Foundation . PDPs are not-for-profit entities formed for the purpose of advancing global health and the health of the world’s poorest by the discovery, development and delivery of new effective and affordable medicines for the most neglected diseases in the world.

The 14 PDPs anticipate funding 128 phase I-IV clinical trials over the next two years 2011-2013. The Bill and Melinda Gates Foundation has committed $10 billion over the next 10 years to help research, develop and deliver vaccines and treatments for the world’s poorest countries, with a portion of that commitment directed to the PDPs. The PDPs also receive funding from government agencies, private entities and other sources.

Quintiles will partner with the consortium members by providing one-step access to Quintiles’ global clinical development infrastructure and standards, particularly in the area of infectious diseases such as HIV, malaria and tuberculosis.

“Quintiles is extremely pleased to have been chosen by the consortium members,” said Dr. Kelly McKee, M.D., Quintiles Vice President and Managing Director, Public Health and Government Services. “The work they’re doing has the potential to reshape global health within a generation. The public health issues on which they are focused has the potential to save millions of lives. We are very excited to be named a preferred provider to the consortium and look forward to helping advance this critical mission.”

Source: Business Wire